Article
Seroprevalence estimate and risk factors for Coxiella burnetii infections among humans in a highly urbanised Brazilian state
Registro en:
MEURER, Igor Rosa et al. Seroprevalence estimate and risk factors for Coxiella burnetii infections among humans in a highly urbanised Brazilian state. Trans. R. Soc. Med Hyg., v. 0, p. 1 - 9, July 2021.
0035-9203
10.1093/trstmh/trab113
Autor
Meurer, Igor Rosa
Silva, Marcio Roberto
Silva, Marcos Vinícius Ferreira
Duré, Ana Íris de Lima
Adelino, Talita Émile Ribeiro
Costa, Alana Vitor Barbosa da
Vanelli, Chislene Pereira
Guimarães, Ricardo José de Paula Souza e
Rozenthal, Tatiana
Lemos, Elba Regina Sampaio de
Corrêa, José Otávio do Amaral
Resumen
Background: Q fever is among the top 13 global priority zoonoses, however, it is still neglected and underreported
in most of the world, including Brazil. Thus, we evaluated the seroprevalence of and the risk factors for
Coxiella burnetii infections in humans from Minas Gerais, a highly urbanised Brazilian state.
Methods: Coxiella burnetii was searched for patient samples (n=437), which were suspected of then later confirmed
as negative for dengue fever, by the indirect immunofluorescence technique and real-time PCR. Risk
factors for infections and spatial clusters for both C. burnetii-seropositive individuals and livestock concentration
were evaluated.
Results: We found that 21 samples (4.8%; 95% CI 3.0 to 7.2%) were reactive for at least one class of anti-C.
burnetii antibodies (titer of ≥64), with rural residence (p=0.036) being a risk factor. Also, two spatial clusters of
seropositivity were found within a significant area by Scan, and a probable relationship between the Scan result
and the livestock concentration by area was found.
Conclusions: Seropositive individuals were associated with rural residence, with a likely relationship with the
livestock concentration. Thus, this study establishes baseline figures for C. burnetii seroprevalence in humans in
a state of Brazil, allowing the monitoring of trends and setting of control targets, as well as more representative
longitudinal and risk analysis studies. 2023